TIDMSCLP
RNS Number : 7303H
Scancell Holdings Plc
22 August 2016
22 August 2016
Scancell Holdings Plc
('Scancell' or the "Company")
Dr Alan J. Lewis appointed as Non-Executive Director
Scancell Holdings Plc, (AIM:SCLP), the developer of novel
immunotherapies for the treatment of cancer, today announces the
appointment of Dr Alan J. Lewis to the Board of Scancell as
Non-Executive Director with immediate effect.
Alan has extensive experience in the US life sciences industry
with a proven track record of raising funds and advancing drug
discovery and development in both biotechnology and large
pharmaceutical companies. Since 2000, as CEO, Alan has successfully
led several life sciences companies through rapid growth to a
successful exit. At Medistem he oversaw the acquisition by Intrexon
in March 2014 for a stock and cash transaction of $26 million.
Whilst at Novocell, he supervised the $25.4 million fundraising and
was responsible for its multi-year drug discovery collaboration
with Pfizer. As CEO of Signal Therapeutics, Alan oversaw multi-year
alliances with a number of leading pharmaceutical companies
including Akzo Nobel, Roche Biosciences and Novartis, and
subsequently managed its $275 million acquisition by Celgene.
Alan has also held senior positions at Celgene, Ambit
Biosciences, and the Juvenile Diabetes Research Foundation and
initially worked in research at Organon Laboratories (Merck) and
Wyeth Laboratories (Pfizer).
He is currently President and CEO of DiaVacs, a San Diego based
clinical stage biotechnology company developing products to reverse
the onset of autoimmune diseases by re-inducing tolerance into the
patient's immune system to halt the vicious cycle of
autoimmunity.
Alan has a B.Sc in Physiology and Biochemistry from Southampton
University, UK, a Ph.D in Pharmacology from the University of
Wales, UK where he was later made an Honorary Research Fellow in
2008. He has held research fellowships at University of Guelph,
Canada and Yale University, USA, and has published over 120 full
manuscripts, 100 abstracts as well as written and edited seven
books.
Speaking upon his appointment, Dr Lewis said: "I am very much
looking forward to joining the Board of Scancell. This is an
exciting time for immuno-oncology and I am delighted to be involved
in the cutting edge science that underpins the company's research
and development."
Dr John Chiplin, Executive Chairman of Scancell continued: "We
welcome Alan to the Scancell Board. He brings with him a wealth of
industry experience, both commercially and financially. Most
importantly though, Alan has extensive experience in drug discovery
and development, which combined with his close connections to key
players in the sector, will be invaluable to Scancell as it begins
to accelerate the development of a range of new products from the
ImmunoBody(R) and Moditope(R) platforms from next year."
Schedule Two information regarding Dr Alan James Lewis, age
70:
Current Directorships
Assembly Biosciences, Inc. (US)
Batu Biologics, Inc. (US)
Biocom (US)
BioMarin Pharmaceutical, Inc. (US)
Capella Therapeutics (US)
Cellastra, Inc. (US)
DiaVacs, Inc. (US)
Habit Rx (US)
International Association of Inflammation Societies (US)
Neurometrix Rx (US)
The Stem Cell Advisors, Inc. (US)
Targazyme, Inc. (US)
Directorships in the past five years
Ambit Biosciences Corporation (US)
Biotica Technology Ltd. (UK)
Cytochroma (CA)
Medistem, Inc. (US)
Rincon Pharmaceuticals (US)
There are no other disclosures required in relation to Rule 17
or paragraph (g) of Schedule 2 of the AIM Rules for Companies.
This announcement contains inside information.
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Executive
Chairman +1 858 900 2646
Dr Richard Goodfellow, Scancell Holdings +44 (0) 20 3727
CEO Plc 1000
Freddy Crossley (Corporate +44 (0) 20 7886
Finance) 2500
Tom Salvesen (Corporate Panmure Gordon +44 (0) 20 7886
Broking) & Co 2500
+44 (0) 20 3727
Mo Noonan/Simon Conway FTI Consulting 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
Scancell's first ImmunoBody(R), SCIB1 is being developed for the
treatment of melanoma. Data from the Phase 1/2 clinical trial
demonstrate that SCIB1, when used as monotherapy, has a marked
effect on tumour load, produces a melanoma-specific immune response
and highly encouraging survival trend without serious side effects.
In patients with resected disease there is increasing evidence to
suggest that SCIB1 may delay or prevent disease recurrence.
Scancell's ImmunoBody(R) vaccines target dendritic cells and
stimulate both parts of the cellular immune system: the helper cell
system where inflammation is stimulated at the tumour site and the
cytotoxic T-lymphocyte or CTL response where immune system cells
are primed to recognise and kill specific cells.
Pre-clinical data on a combination of SCIB1 or SCIB2 and
checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune
checkpoint pathways) have shown enhanced tumour destruction and
significantly longer survival times than when either treatment was
used alone.
Scancell has also identified and patented a series of modified
epitopes that stimulate the production of killer CD4+ T cells that
destroy tumours without toxicity. The Directors believe that the
Moditope(R) platform could play a major role in the development of
safe and effective cancer immunotherapies in the future.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPBMRTMBITBPF
(END) Dow Jones Newswires
August 22, 2016 02:00 ET (06:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2024 to Jun 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Jun 2023 to Jun 2024